The graphic situation of Diasorin, as we will see later in this article, is quite uncertain and clashes with the positive news arriving on the title. For example, the company recently received the green light from the FDA (Food and Drug Administration) to market some of its products in the United States of America for the identification of monkeypox. Furthermore, the company is focusing heavily on new technological platforms for use in pharmacies and small outpatient clinics.
However, the share on the Stock Exchange is probably suffering due to the weakness of the data relating to the first 9 months of 2022. Diasorin, in fact, closed the first nine months of the year with a net profit of 203 million euros, -11.5% compared to the first 9 months of 2021 and an incidence on revenues of 20%. In addition, net financial debt rose to -1.012 billion euros from -986 million euros as at 31 December 2021.
This explains why those Diasorin shares, at least in this phase, remain in the balance, but interesting in the long term. In fact, we recall that Diasorin belongs to that category of securities which, with the history available, after an investment of more than or equal to 10 years has a 100% probability of giving a positive return. Obviously this is no guarantee for the future, but it is certainly a good starting point.
According to analysts’ recommendations, the average target price expresses an undervaluation of around 11%.
Shares in the balance, but interesting in the long term: the indications of the graphic analysis
The title Diasorin (MIL:DSA) closed the November 24 session at €133.20, up 0.57% on the previous session.
The current projection is bearish and sees the quotations frozen for a few days between the strong support in the 129.65 euro area and the resistance in the 133.39 euro area. Only the break of one of these two levels could give directionality to the quotations.
On the downside, the probable targets are those indicated in the figure with a probable maximum extension in the 110 euro area (III price target). On the upside, however, the objectives can only be calculated with a confirmed reversal. In any case we can hypothesize a return above 150 euros per share.